Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder

Guido Dalbagni, Dipen J Parekh, Leah Ben-Porat, Michele Potenzoni, Harry W. Herr, Victor E. Reuter

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

OBJECTIVE: To prospectively evaluate p53 overexpression as a predictor of survival in patients with a first diagnosis of T1 transitional cell carcinoma (TCC) of the bladder, as several reports implicate p53 as an important prognostic marker for progression and survival, but all previous studies were retrospective, giving conflicting and irreproducible results, rendering inappropriate any attempt at integrating p53 into clinical decision-making. PATIENTS AND METHODS: Patients with a first diagnosis of T1 TCC of the bladder were enrolled; p53 overexpression was assessed by immunohistochemistry (IHC) using both monoclonal antibody 1801 and DO7. The pathological stage and IHC score were assigned by one pathologist, and the markers were scored categorically. RESULTS: Of the 89 patients who were evaluable, 53 had p53-positive tumours. The median follow-up for the survivors was 52 months. Eighty-two patients had high-grade tumours, using the World Health Organisation/International Society of Urological Pathology 1998 grading system. Fifty-eight patients had unifocal tumours and 34 had associated carcinoma in situ. During the follow-up, 34 additional patients had a radical cystectomy and nine died from bladder cancer. The association of p53 overexpression with progression or survival was not significant. CONCLUSIONS: p53 tissue typing by IHC in a prospective cohort of patients with T1 bladder cancer was not clinically useful as a prognostic marker in a contemporary series of T1 tumours.

Original languageEnglish
Pages (from-to)281-285
Number of pages5
JournalBJU International
Volume99
Issue number2
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Transitional Cell Carcinoma
Urinary Bladder
Immunohistochemistry
Urinary Bladder Neoplasms
Survival
Neoplasms
Histocompatibility Testing
Cystectomy
Carcinoma in Situ
Survivors
Retrospective Studies
Monoclonal Antibodies
Pathology

Keywords

  • Bladder cancer
  • Markers
  • p53
  • Survival
  • T1

ASJC Scopus subject areas

  • Urology

Cite this

Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. / Dalbagni, Guido; Parekh, Dipen J; Ben-Porat, Leah; Potenzoni, Michele; Herr, Harry W.; Reuter, Victor E.

In: BJU International, Vol. 99, No. 2, 01.02.2007, p. 281-285.

Research output: Contribution to journalArticle

Dalbagni, Guido ; Parekh, Dipen J ; Ben-Porat, Leah ; Potenzoni, Michele ; Herr, Harry W. ; Reuter, Victor E. / Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. In: BJU International. 2007 ; Vol. 99, No. 2. pp. 281-285.
@article{6e81bffbdc7049e387b79983a2342834,
title = "Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder",
abstract = "OBJECTIVE: To prospectively evaluate p53 overexpression as a predictor of survival in patients with a first diagnosis of T1 transitional cell carcinoma (TCC) of the bladder, as several reports implicate p53 as an important prognostic marker for progression and survival, but all previous studies were retrospective, giving conflicting and irreproducible results, rendering inappropriate any attempt at integrating p53 into clinical decision-making. PATIENTS AND METHODS: Patients with a first diagnosis of T1 TCC of the bladder were enrolled; p53 overexpression was assessed by immunohistochemistry (IHC) using both monoclonal antibody 1801 and DO7. The pathological stage and IHC score were assigned by one pathologist, and the markers were scored categorically. RESULTS: Of the 89 patients who were evaluable, 53 had p53-positive tumours. The median follow-up for the survivors was 52 months. Eighty-two patients had high-grade tumours, using the World Health Organisation/International Society of Urological Pathology 1998 grading system. Fifty-eight patients had unifocal tumours and 34 had associated carcinoma in situ. During the follow-up, 34 additional patients had a radical cystectomy and nine died from bladder cancer. The association of p53 overexpression with progression or survival was not significant. CONCLUSIONS: p53 tissue typing by IHC in a prospective cohort of patients with T1 bladder cancer was not clinically useful as a prognostic marker in a contemporary series of T1 tumours.",
keywords = "Bladder cancer, Markers, p53, Survival, T1",
author = "Guido Dalbagni and Parekh, {Dipen J} and Leah Ben-Porat and Michele Potenzoni and Herr, {Harry W.} and Reuter, {Victor E.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1111/j.1464-410X.2006.06624.x",
language = "English",
volume = "99",
pages = "281--285",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder

AU - Dalbagni, Guido

AU - Parekh, Dipen J

AU - Ben-Porat, Leah

AU - Potenzoni, Michele

AU - Herr, Harry W.

AU - Reuter, Victor E.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - OBJECTIVE: To prospectively evaluate p53 overexpression as a predictor of survival in patients with a first diagnosis of T1 transitional cell carcinoma (TCC) of the bladder, as several reports implicate p53 as an important prognostic marker for progression and survival, but all previous studies were retrospective, giving conflicting and irreproducible results, rendering inappropriate any attempt at integrating p53 into clinical decision-making. PATIENTS AND METHODS: Patients with a first diagnosis of T1 TCC of the bladder were enrolled; p53 overexpression was assessed by immunohistochemistry (IHC) using both monoclonal antibody 1801 and DO7. The pathological stage and IHC score were assigned by one pathologist, and the markers were scored categorically. RESULTS: Of the 89 patients who were evaluable, 53 had p53-positive tumours. The median follow-up for the survivors was 52 months. Eighty-two patients had high-grade tumours, using the World Health Organisation/International Society of Urological Pathology 1998 grading system. Fifty-eight patients had unifocal tumours and 34 had associated carcinoma in situ. During the follow-up, 34 additional patients had a radical cystectomy and nine died from bladder cancer. The association of p53 overexpression with progression or survival was not significant. CONCLUSIONS: p53 tissue typing by IHC in a prospective cohort of patients with T1 bladder cancer was not clinically useful as a prognostic marker in a contemporary series of T1 tumours.

AB - OBJECTIVE: To prospectively evaluate p53 overexpression as a predictor of survival in patients with a first diagnosis of T1 transitional cell carcinoma (TCC) of the bladder, as several reports implicate p53 as an important prognostic marker for progression and survival, but all previous studies were retrospective, giving conflicting and irreproducible results, rendering inappropriate any attempt at integrating p53 into clinical decision-making. PATIENTS AND METHODS: Patients with a first diagnosis of T1 TCC of the bladder were enrolled; p53 overexpression was assessed by immunohistochemistry (IHC) using both monoclonal antibody 1801 and DO7. The pathological stage and IHC score were assigned by one pathologist, and the markers were scored categorically. RESULTS: Of the 89 patients who were evaluable, 53 had p53-positive tumours. The median follow-up for the survivors was 52 months. Eighty-two patients had high-grade tumours, using the World Health Organisation/International Society of Urological Pathology 1998 grading system. Fifty-eight patients had unifocal tumours and 34 had associated carcinoma in situ. During the follow-up, 34 additional patients had a radical cystectomy and nine died from bladder cancer. The association of p53 overexpression with progression or survival was not significant. CONCLUSIONS: p53 tissue typing by IHC in a prospective cohort of patients with T1 bladder cancer was not clinically useful as a prognostic marker in a contemporary series of T1 tumours.

KW - Bladder cancer

KW - Markers

KW - p53

KW - Survival

KW - T1

UR - http://www.scopus.com/inward/record.url?scp=33846262187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846262187&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2006.06624.x

DO - 10.1111/j.1464-410X.2006.06624.x

M3 - Article

C2 - 17155984

AN - SCOPUS:33846262187

VL - 99

SP - 281

EP - 285

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -